<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01059175</url>
  </required_header>
  <id_info>
    <org_study_id>Medtronic</org_study_id>
    <nct_id>NCT01059175</nct_id>
  </id_info>
  <brief_title>Dual-Site LV Pacing in CRT Non Responders: Multicenter Randomized Trial</brief_title>
  <acronym>V3</acronym>
  <official_title>Dual-Site LV Pacing in CRT Non Responders Multicenter Randomized V3 Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Bakken Research Center</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>FRANCE</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medtronic Bakken Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiac resynchronization therapy (CRT) is an effective treatment of heart failure (HF)
      refractory to optimal medical management, in presence of a depressed left ventricular (LV)
      ejection fraction and a wide QRS complex. It is mainly limited by a high proportion of
      non-responders. Attempts have been made, in small studies, to increase the number of
      stimulation sites in order to optimize the resynchronization therapy. V3 is a planned
      multicenter, randomized trial whose objective is to evaluate the clinical benefit conferred
      by the addition of a second endocardial or epicardial LV lead in non-responders after at
      least 6 months of standard biventricular stimulation.

      The V3 trial will examine the clinical benefit conferred by the addition of a second LV lead
      in non-responders compared to standard CRT.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Distribution of &quot;Improved&quot;, &quot;Unchanged&quot; and &quot;Worsened&quot; Patients as Defined Per M. Packer's Clinical Composite Score</measure>
    <time_frame>12 months</time_frame>
    <description>M. Packer's clinical composite score: patients were classified into 1 of 3 response groups after 12 months follow up : worsened, unchanged, or improved.
Worsened : if death, hospitalization because of or associated with worsening HF, demonstrated worsening in NYHA functional class at their 12-month visit, or if investigator judges global clinical state has worsened.
Improved :if they had not worsened and had demonstrated improvement in NYHA functional class, or or if investigator judges global clinical state has improved.
Unchanged : if none of the previous definition applies.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Distribution of &quot;Improved&quot;, &quot;Unchanged&quot; and &quot;Worsened&quot; Patients as Defined Per M. Packer's Clinical Composite Score</measure>
    <time_frame>24 months</time_frame>
    <description>Distribution of &quot;improved&quot;, &quot;unchanged&quot; and &quot;worsened&quot; patients as defined per M. Packer's clinical composite score at 24 months post implantation of the second left ventricle lead in comparison to the control group M. Packer's clinical composite score: patients were classified into 1 of 3 response groups after 24 months follow up : worsened, unchanged, or improved.
Worsened : if death, hospitalization because of or associated with worsening HF, demonstrated worsening in NYHA functional class at their 24-month visit, or if investigator judges global clinical state has worsened.
Improved :if they had not worsened and had demonstrated improvement in NYHA functional class, or or if investigator judges global clinical state has improved.
Unchanged : if none of the previous definition applies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Adverse Events</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in 6 Minutes Hall Walk Distance Observed Between the Enrollment and the End of the Study</measure>
    <time_frame>24 months</time_frame>
    <description>Changes between baseline and 24months follow up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With at Least One Hospitalization Related to Heart Failure Between Randomization and the End of the Study</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Heart Failure Related Hospitalization</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Mortality</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Echocardiographic Indexes of Left Ventricle Remodeling</measure>
    <time_frame>24 months</time_frame>
    <description>Changes between baseline and 24months follow up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Quality of Life Score - Minesota Living With Heart Failure Questionnaire</measure>
    <time_frame>24 months</time_frame>
    <description>Changes between baseline and 24 months follow up Minesota Living with Heart Failure Questionnaire: 21 questions - addition of scores from 1 (better) to 5 (worse) for each questions.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>CRT With Dual Site LV Pacing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cardiac resynchronization therapy with the addition of a second LV lead. Positioning of a pacing lead in a cardiac vein should be considered first. An epicardial lead will be used if the implant of an endocardial lead is impossible or previously failed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard CRT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional cardiac resynchronization therapy. Patients in this arm will keep their CRT system unchanged.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Additional Endocardial or Epicardial LV Lead</intervention_name>
    <description>Addition of a second left ventricular endocardial or epicardial lead</description>
    <arm_group_label>CRT With Dual Site LV Pacing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CRT-P or CRT-D</intervention_name>
    <description>Implantable Cardiac Resynchronization Therapy Pacemaker (CRT-P) or Defibrillator (CRT-D) Device</description>
    <arm_group_label>CRT With Dual Site LV Pacing</arm_group_label>
    <arm_group_label>Standard CRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age greater than 18 years

          -  Recipient of a CRT-P or CRT-D system for greater than 6 for standard indications,
             including LV ejection fraction greater than 35 percent and New York Heart Association
             (NYHA) functional class III or IV

          -  Optimized biventricular stimulation and medical therapy since implantation of the
             system

          -  Presence of sinus rhythm, or atrial fibrillation with spontaneous or induced complete
             atrio-ventricular block

          -  Greater than 93 percent LV stimulation since the last device interrogation, with a LV
             capture threshold less than 5.0 Volts/0.5 milliseconds

          -  Unchanged or worsened clinical status by CRT, according to the HF composite endpoint
             described by M. Packer, in absence of a reversible cause

          -  Signature of a written, informed consent to participate in the trial

        Exclusion Criteria:

          -  LV lead location in the great cardiac vein

          -  Life-expectancy less than 1 year due to concomitant, non-cardiovascular disorders

          -  Chronic renal dialysis

          -  Concomitant disorder which might interfere with the results of the V3 trial

          -  Blood systolic pressure greater than 180 millimeters of mercury (mmHg) or diastolic
             pressure greater than 95 mmHg despite optimal medical management

          -  History of stroke, myocardial infarction or unstable angina pectoris within the last 3
             months

          -  Presence of correctible valvular disease

          -  Subject unable to attend follow-up at the investigative center or unable, for physical
             or mental reasons, to comply with the trial's procedures, or to sign the informed
             consent

          -  Subject is pregnant

          -  Subject participates in another research project
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bordachar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Bordeaux</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University hospital Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Bordachar P, Alonso C, Anselme F, Boveda S, Defaye P, Garrigue S, Gras D, Klug D, Piot O, Sadoul N, Leclercq C. Addition of a second LV pacing site in CRT nonresponders rationale and design of the multicenter randomized V(3) trial. J Card Fail. 2010 Sep;16(9):709-13. doi: 10.1016/j.cardfail.2010.04.010. Epub 2010 Jun 8.</citation>
    <PMID>20797593</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2010</study_first_submitted>
  <study_first_submitted_qc>January 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2010</study_first_posted>
  <results_first_submitted>May 25, 2016</results_first_submitted>
  <results_first_submitted_qc>April 18, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 21, 2017</results_first_posted>
  <last_update_submitted>April 18, 2017</last_update_submitted>
  <last_update_submitted_qc>April 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart failure</keyword>
  <keyword>Cardiac resynchronization therapy</keyword>
  <keyword>Biventricular stimulation</keyword>
  <keyword>Multisite stimulation</keyword>
  <keyword>Non responders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CRT With Dual Site LV Pacing</title>
          <description>Cardiac resynchronization therapy with the addition of a second LV lead. Positioning of a pacing lead in a cardiac vein should be considered first. An epicardial lead will be used if the implant of an endocardial lead is impossible or previously failed.
Additional Endocardial or Epicardial LV Lead: Addition of a second left ventricular endocardial or epicardial lead
CRT-P or CRT-D: Implantable Cardiac Resynchronization Therapy Pacemaker (CRT-P) or Defibrillator (CRT-D) Device</description>
        </group>
        <group group_id="P2">
          <title>Standard CRT</title>
          <description>Conventional cardiac resynchronization therapy. Patients in this arm will keep their CRT system unchanged.
CRT-P or CRT-D: Implantable Cardiac Resynchronization Therapy Pacemaker (CRT-P) or Defibrillator (CRT-D) Device</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22">17 patients deceased 4 additional patients were prematurely exited</participants>
                <participants group_id="P2" count="21">17 patients deceased 3 patients were prematurely exited</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>One patient of the V3 group was not included in the ITT analysis of efficacy results as he did not meet inclusion criteria so 83 pts were analyzed</population>
      <group_list>
        <group group_id="B1">
          <title>CRT With Dual Site LV Pacing</title>
          <description>Cardiac resynchronization therapy with the addition of a second LV lead. Positioning of a pacing lead in a cardiac vein should be considered first. An epicardial lead will be used if the implant of an endocardial lead is impossible or previously failed.
Additional Endocardial or Epicardial LV Lead: Addition of a second left ventricular endocardial or epicardial lead
CRT-P or CRT-D: Implantable Cardiac Resynchronization Therapy Pacemaker (CRT-P) or Defibrillator (CRT-D) Device</description>
        </group>
        <group group_id="B2">
          <title>Standard CRT</title>
          <description>Conventional cardiac resynchronization therapy. Patients in this arm will keep their CRT system unchanged.
CRT-P or CRT-D: Implantable Cardiac Resynchronization Therapy Pacemaker (CRT-P) or Defibrillator (CRT-D) Device</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
            <count group_id="B2" value="41"/>
            <count group_id="B3" value="83"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.5" spread="7.7"/>
                    <measurement group_id="B2" value="72.2" spread="7.9"/>
                    <measurement group_id="B3" value="71.3" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patients with ischemic heart disease</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Paced QRS duration</title>
          <units>milliseconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="165" spread="30.5"/>
                    <measurement group_id="B2" value="155" spread="42.2"/>
                    <measurement group_id="B3" value="160" spread="36.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time from first CRT implant</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.5" spread="28.4"/>
                    <measurement group_id="B2" value="37.8" spread="23.7"/>
                    <measurement group_id="B3" value="40.6" spread="26.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>LVEF % (left ventricle ejection fraction)</title>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.9" spread="6.0"/>
                    <measurement group_id="B2" value="25.9" spread="7.0"/>
                    <measurement group_id="B3" value="26.4" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>LVEDV (left ventricular end-diastolic volume)</title>
          <units>milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="219" spread="85.8"/>
                    <measurement group_id="B2" value="206" spread="63.9"/>
                    <measurement group_id="B3" value="213" spread="75.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>LVESV (left ventricular end-systolic volume)</title>
          <units>milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="154" spread="61.8"/>
                    <measurement group_id="B2" value="149" spread="58.7"/>
                    <measurement group_id="B3" value="151" spread="59.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Distribution of &quot;Improved&quot;, &quot;Unchanged&quot; and &quot;Worsened&quot; Patients as Defined Per M. Packer's Clinical Composite Score</title>
        <description>M. Packer's clinical composite score: patients were classified into 1 of 3 response groups after 12 months follow up : worsened, unchanged, or improved.
Worsened : if death, hospitalization because of or associated with worsening HF, demonstrated worsening in NYHA functional class at their 12-month visit, or if investigator judges global clinical state has worsened.
Improved :if they had not worsened and had demonstrated improvement in NYHA functional class, or or if investigator judges global clinical state has improved.
Unchanged : if none of the previous definition applies.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CRT With Dual Site LV Pacing</title>
            <description>Cardiac resynchronization therapy with the addition of a second LV lead. Positioning of a pacing lead in a cardiac vein should be considered first. An epicardial lead will be used if the implant of an endocardial lead is impossible or previously failed.
Additional Endocardial or Epicardial LV Lead: Addition of a second left ventricular endocardial or epicardial lead
CRT-P or CRT-D: Implantable Cardiac Resynchronization Therapy Pacemaker (CRT-P) or Defibrillator (CRT-D) Device</description>
          </group>
          <group group_id="O2">
            <title>Standard CRT</title>
            <description>Conventional cardiac resynchronization therapy. Patients in this arm will keep their CRT system unchanged.
CRT-P or CRT-D: Implantable Cardiac Resynchronization Therapy Pacemaker (CRT-P) or Defibrillator (CRT-D) Device</description>
          </group>
        </group_list>
        <measure>
          <title>Distribution of &quot;Improved&quot;, &quot;Unchanged&quot; and &quot;Worsened&quot; Patients as Defined Per M. Packer's Clinical Composite Score</title>
          <description>M. Packer's clinical composite score: patients were classified into 1 of 3 response groups after 12 months follow up : worsened, unchanged, or improved.
Worsened : if death, hospitalization because of or associated with worsening HF, demonstrated worsening in NYHA functional class at their 12-month visit, or if investigator judges global clinical state has worsened.
Improved :if they had not worsened and had demonstrated improvement in NYHA functional class, or or if investigator judges global clinical state has improved.
Unchanged : if none of the previous definition applies.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Improved patients</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unchanged patients</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worsened patients</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Distribution of &quot;Improved&quot;, &quot;Unchanged&quot; and &quot;Worsened&quot; Patients as Defined Per M. Packer's Clinical Composite Score</title>
        <description>Distribution of &quot;improved&quot;, &quot;unchanged&quot; and &quot;worsened&quot; patients as defined per M. Packer's clinical composite score at 24 months post implantation of the second left ventricle lead in comparison to the control group M. Packer's clinical composite score: patients were classified into 1 of 3 response groups after 24 months follow up : worsened, unchanged, or improved.
Worsened : if death, hospitalization because of or associated with worsening HF, demonstrated worsening in NYHA functional class at their 24-month visit, or if investigator judges global clinical state has worsened.
Improved :if they had not worsened and had demonstrated improvement in NYHA functional class, or or if investigator judges global clinical state has improved.
Unchanged : if none of the previous definition applies.</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CRT With Dual Site LV Pacing</title>
            <description>Cardiac resynchronization therapy with the addition of a second LV lead. Positioning of a pacing lead in a cardiac vein should be considered first. An epicardial lead will be used if the implant of an endocardial lead is impossible or previously failed.
Additional Endocardial or Epicardial LV Lead: Addition of a second left ventricular endocardial or epicardial lead
CRT-P or CRT-D: Implantable Cardiac Resynchronization Therapy Pacemaker (CRT-P) or Defibrillator (CRT-D) Device</description>
          </group>
          <group group_id="O2">
            <title>Standard CRT</title>
            <description>Conventional cardiac resynchronization therapy. Patients in this arm will keep their CRT system unchanged.
CRT-P or CRT-D: Implantable Cardiac Resynchronization Therapy Pacemaker (CRT-P) or Defibrillator (CRT-D) Device</description>
          </group>
        </group_list>
        <measure>
          <title>Distribution of &quot;Improved&quot;, &quot;Unchanged&quot; and &quot;Worsened&quot; Patients as Defined Per M. Packer's Clinical Composite Score</title>
          <description>Distribution of &quot;improved&quot;, &quot;unchanged&quot; and &quot;worsened&quot; patients as defined per M. Packer's clinical composite score at 24 months post implantation of the second left ventricle lead in comparison to the control group M. Packer's clinical composite score: patients were classified into 1 of 3 response groups after 24 months follow up : worsened, unchanged, or improved.
Worsened : if death, hospitalization because of or associated with worsening HF, demonstrated worsening in NYHA functional class at their 24-month visit, or if investigator judges global clinical state has worsened.
Improved :if they had not worsened and had demonstrated improvement in NYHA functional class, or or if investigator judges global clinical state has improved.
Unchanged : if none of the previous definition applies.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patients improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients worsened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Adverse Events</title>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CRT With Dual Site LV Pacing</title>
            <description>Cardiac resynchronization therapy with the addition of a second LV lead. Positioning of a pacing lead in a cardiac vein should be considered first. An epicardial lead will be used if the implant of an endocardial lead is impossible or previously failed.
Additional Endocardial or Epicardial LV Lead: Addition of a second left ventricular endocardial or epicardial lead
CRT-P or CRT-D: Implantable Cardiac Resynchronization Therapy Pacemaker (CRT-P) or Defibrillator (CRT-D) Device</description>
          </group>
          <group group_id="O2">
            <title>Standard CRT</title>
            <description>Conventional cardiac resynchronization therapy. Patients in this arm will keep their CRT system unchanged.
CRT-P or CRT-D: Implantable Cardiac Resynchronization Therapy Pacemaker (CRT-P) or Defibrillator (CRT-D) Device</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Adverse Events</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patients with at least one AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with at least one severe AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in 6 Minutes Hall Walk Distance Observed Between the Enrollment and the End of the Study</title>
        <description>Changes between baseline and 24months follow up</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CRT With Dual Site LV Pacing</title>
            <description>Cardiac resynchronization therapy with the addition of a second LV lead. Positioning of a pacing lead in a cardiac vein should be considered first. An epicardial lead will be used if the implant of an endocardial lead is impossible or previously failed.
Additional Endocardial or Epicardial LV Lead: Addition of a second left ventricular endocardial or epicardial lead
CRT-P or CRT-D: Implantable Cardiac Resynchronization Therapy Pacemaker (CRT-P) or Defibrillator (CRT-D) Device</description>
          </group>
          <group group_id="O2">
            <title>Standard CRT</title>
            <description>Conventional cardiac resynchronization therapy. Patients in this arm will keep their CRT system unchanged.
CRT-P or CRT-D: Implantable Cardiac Resynchronization Therapy Pacemaker (CRT-P) or Defibrillator (CRT-D) Device</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in 6 Minutes Hall Walk Distance Observed Between the Enrollment and the End of the Study</title>
          <description>Changes between baseline and 24months follow up</description>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.1" spread="88.0"/>
                    <measurement group_id="O2" value="7.5" spread="96.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With at Least One Hospitalization Related to Heart Failure Between Randomization and the End of the Study</title>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CRT With Dual Site LV Pacing</title>
            <description>Cardiac resynchronization therapy with the addition of a second LV lead. Positioning of a pacing lead in a cardiac vein should be considered first. An epicardial lead will be used if the implant of an endocardial lead is impossible or previously failed.
Additional Endocardial or Epicardial LV Lead: Addition of a second left ventricular endocardial or epicardial lead
CRT-P or CRT-D: Implantable Cardiac Resynchronization Therapy Pacemaker (CRT-P) or Defibrillator (CRT-D) Device</description>
          </group>
          <group group_id="O2">
            <title>Standard CRT</title>
            <description>Conventional cardiac resynchronization therapy. Patients in this arm will keep their CRT system unchanged.
CRT-P or CRT-D: Implantable Cardiac Resynchronization Therapy Pacemaker (CRT-P) or Defibrillator (CRT-D) Device</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With at Least One Hospitalization Related to Heart Failure Between Randomization and the End of the Study</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Heart Failure Related Hospitalization</title>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CRT With Dual Site LV Pacing</title>
            <description>Cardiac resynchronization therapy with the addition of a second LV lead. Positioning of a pacing lead in a cardiac vein should be considered first. An epicardial lead will be used if the implant of an endocardial lead is impossible or previously failed.
Additional Endocardial or Epicardial LV Lead: Addition of a second left ventricular endocardial or epicardial lead
CRT-P or CRT-D: Implantable Cardiac Resynchronization Therapy Pacemaker (CRT-P) or Defibrillator (CRT-D) Device</description>
          </group>
          <group group_id="O2">
            <title>Standard CRT</title>
            <description>Conventional cardiac resynchronization therapy. Patients in this arm will keep their CRT system unchanged.
CRT-P or CRT-D: Implantable Cardiac Resynchronization Therapy Pacemaker (CRT-P) or Defibrillator (CRT-D) Device</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Heart Failure Related Hospitalization</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="357.6" spread="27.17"/>
                    <measurement group_id="O2" value="402.4" spread="41.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Mortality</title>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CRT With Dual Site LV Pacing</title>
            <description>Cardiac resynchronization therapy with the addition of a second LV lead. Positioning of a pacing lead in a cardiac vein should be considered first. An epicardial lead will be used if the implant of an endocardial lead is impossible or previously failed.
Additional Endocardial or Epicardial LV Lead: Addition of a second left ventricular endocardial or epicardial lead
CRT-P or CRT-D: Implantable Cardiac Resynchronization Therapy Pacemaker (CRT-P) or Defibrillator (CRT-D) Device</description>
          </group>
          <group group_id="O2">
            <title>Standard CRT</title>
            <description>Conventional cardiac resynchronization therapy. Patients in this arm will keep their CRT system unchanged.
CRT-P or CRT-D: Implantable Cardiac Resynchronization Therapy Pacemaker (CRT-P) or Defibrillator (CRT-D) Device</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Mortality</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Echocardiographic Indexes of Left Ventricle Remodeling</title>
        <description>Changes between baseline and 24months follow up</description>
        <time_frame>24 months</time_frame>
        <population>Number of patients with data available for analysis of this objective</population>
        <group_list>
          <group group_id="O1">
            <title>CRT With Dual Site LV Pacing</title>
            <description>Cardiac resynchronization therapy with the addition of a second LV lead. Positioning of a pacing lead in a cardiac vein should be considered first. An epicardial lead will be used if the implant of an endocardial lead is impossible or previously failed.
Additional Endocardial or Epicardial LV Lead: Addition of a second left ventricular endocardial or epicardial lead
CRT-P or CRT-D: Implantable Cardiac Resynchronization Therapy Pacemaker (CRT-P) or Defibrillator (CRT-D) Device</description>
          </group>
          <group group_id="O2">
            <title>Standard CRT</title>
            <description>Conventional cardiac resynchronization therapy. Patients in this arm will keep their CRT system unchanged.
CRT-P or CRT-D: Implantable Cardiac Resynchronization Therapy Pacemaker (CRT-P) or Defibrillator (CRT-D) Device</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Echocardiographic Indexes of Left Ventricle Remodeling</title>
          <description>Changes between baseline and 24months follow up</description>
          <population>Number of patients with data available for analysis of this objective</population>
          <units>milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Changes in LVEDV</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.4" spread="78.6"/>
                    <measurement group_id="O2" value="7.0" spread="72.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Changes in LVESV</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.3" spread="57.6"/>
                    <measurement group_id="O2" value="-2.0" spread="60.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Quality of Life Score - Minesota Living With Heart Failure Questionnaire</title>
        <description>Changes between baseline and 24 months follow up Minesota Living with Heart Failure Questionnaire: 21 questions - addition of scores from 1 (better) to 5 (worse) for each questions.</description>
        <time_frame>24 months</time_frame>
        <population>Number of patients with data available for analysis of this objective</population>
        <group_list>
          <group group_id="O1">
            <title>CRT With Dual Site LV Pacing</title>
            <description>Cardiac resynchronization therapy with the addition of a second LV lead. Positioning of a pacing lead in a cardiac vein should be considered first. An epicardial lead will be used if the implant of an endocardial lead is impossible or previously failed.
Additional Endocardial or Epicardial LV Lead: Addition of a second left ventricular endocardial or epicardial lead
CRT-P or CRT-D: Implantable Cardiac Resynchronization Therapy Pacemaker (CRT-P) or Defibrillator (CRT-D) Device</description>
          </group>
          <group group_id="O2">
            <title>Standard CRT</title>
            <description>Conventional cardiac resynchronization therapy. Patients in this arm will keep their CRT system unchanged.
CRT-P or CRT-D: Implantable Cardiac Resynchronization Therapy Pacemaker (CRT-P) or Defibrillator (CRT-D) Device</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Quality of Life Score - Minesota Living With Heart Failure Questionnaire</title>
          <description>Changes between baseline and 24 months follow up Minesota Living with Heart Failure Questionnaire: 21 questions - addition of scores from 1 (better) to 5 (worse) for each questions.</description>
          <population>Number of patients with data available for analysis of this objective</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.33" spread="23.5"/>
                    <measurement group_id="O2" value="-7.48" spread="17.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>CRT With Dual Site LV Pacing</title>
          <description>Cardiac resynchronization therapy with the addition of a second LV lead. Positioning of a pacing lead in a cardiac vein should be considered first. An epicardial lead will be used if the implant of an endocardial lead is impossible or previously failed.
Additional Endocardial or Epicardial LV Lead: Addition of a second left ventricular endocardial or epicardial lead
CRT-P or CRT-D: Implantable Cardiac Resynchronization Therapy Pacemaker (CRT-P) or Defibrillator (CRT-D) Device</description>
        </group>
        <group group_id="E2">
          <title>Standard CRT</title>
          <description>Conventional cardiac resynchronization therapy. Patients in this arm will keep their CRT system unchanged.
CRT-P or CRT-D: Implantable Cardiac Resynchronization Therapy Pacemaker (CRT-P) or Defibrillator (CRT-D) Device</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Severe cardiovascular event</sub_title>
                <description>Definition as per ISO 14155</description>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac AE</sub_title>
                <description>Definition as per ISO 14155</description>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Latifa Foudali</name_or_title>
      <organization>Medtronic</organization>
      <phone>+33 631992144</phone>
      <email>latifa.foudali@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

